Margin execution and improving underlying demand offset near-term cell-therapy timing, but Q2 faces an approximately 400-basis-point headwind.
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2025-11-05 |
| Length | 56 minutes |
| EPS | $0.36 |
| EPS consensus | $0.36 |
| Revenue | $286.6M |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q3 FY26 · Q2 FY26 · Q4 FY25 · Q3 FY25
Read the full Q1 FY26 earnings call transcript
All TECH earnings · Back to TECH overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.